Healthcare Global Enterprises Limited — Investor Meet, 30-05-2025: Analysts/Institutional Investor Meet/Con. Call Updates

HealthCare Global Enterprises delivered 16% revenue growth to INR2,223 Cr and 17% EBITDA growth to INR396 Cr with a 17.8% margin in FY25. Q4 revenue (excl. Milann) rose 20% YoY to INR571 Cr with an 18.3% EBITDA margin. Emerging centers grew revenue 32% and EBITDA 44%, narrowing margins versus established ones. Digital revenue doubled, supported by a new patient app and SEO. ARPOB rose 4% to ~INR44,236; metro centers approach INR1 Lakh. Expansion adds ~900 beds via new centers in Ahmedabad and Bangalore. PAT was INR44 Cr, impacted by higher depreciation and interest; equity infusion may lower debt. Management focuses on cancer care leadership through technology, precision medicine, and education, with steady international revenue. Milann’s weak business is set for divestment. Outlook remains positive on margin improvement and digital growth, emphasizing early diagnosis and access.